CIK 0001420720
- Non-accelerated filer
- Smaller reporting company
iBio, Inc.
Sign in to watch- Ticker
- IBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 262797813
- Phone
- +1 302-355-0650
- Business address
- 600 MADISON AVENUE, SUITE 1601, NEW YORK, NY, 10022-1737
- Former names
- iBio, Inc., iBioPharma, Inc., InB:Biotechnologies, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-02-20 | Kay Robert Executive Chairman and CEO | Returned to the company · Stock Option (right to buy) | −30,000 | 307,500 | ||
| 2019-02-20 | Kay Robert Executive Chairman and CEO | Grant or award · Stock Option (right to buy) | +22,500 | 307,500 | ||
| 2019-02-20 | Kay Robert Executive Chairman and CEO | Returned to the company · Stock Option (right to buy) | −30,000 | 307,500 | ||
| 2019-02-20 | Kay Robert Executive Chairman and CEO | Grant or award · Stock Option (right to buy) | +22,500 | 307,500 | ||
| 2019-02-20 | Kay Robert Executive Chairman and CEO | Returned to the company · Stock Option (right to buy) | −30,000 | 307,500 | ||
| 2019-02-20 | Kay Robert Executive Chairman and CEO | Grant or award · Stock Option (right to buy) | +22,500 | 307,500 | ||
| 2019-02-20 | Kay Robert Executive Chairman and CEO | Returned to the company · Stock Option (right to buy) | −60,000 | 307,500 | ||
| 2019-02-20 | Kay Robert Executive Chairman and CEO | Grant or award · Stock Option (right to buy) | +45,000 | 307,500 | ||
| 2019-02-20 | Kay Robert Executive Chairman and CEO | Returned to the company · Stock Option (right to buy) | −75,000 | 307,500 | ||
| 2019-02-20 | Kay Robert Executive Chairman and CEO | Grant or award · Stock Option (right to buy) | +56,250 | 307,500 | ||
| 2019-02-20 | Kay Robert Executive Chairman and CEO | Returned to the company · Stock Option (right to buy) | −30,000 | 307,500 | ||
| 2019-02-20 | Kay Robert Executive Chairman and CEO | Grant or award · Stock Option (right to buy) | +22,500 | 307,500 | ||
| 2019-02-20 | ERWIN ROBERT L President | Returned to the company · Stock Option (right to buy) | −25,000 | 232,500 | ||
| 2019-02-20 | ERWIN ROBERT L President | Grant or award · Stock Option (right to buy) | +18,750 | 232,500 | ||
| 2019-02-20 | ERWIN ROBERT L President | Returned to the company · Stock Option (right to buy) | −30,000 | 232,500 | ||
| 2019-02-20 | ERWIN ROBERT L President | Grant or award · Stock Option (right to buy) | +22,500 | 232,500 | ||
| 2019-02-20 | ERWIN ROBERT L President | Returned to the company · Stock Option (right to buy) | −30,000 | 232,500 | ||
| 2019-02-20 | ERWIN ROBERT L President | Grant or award · Stock Option (right to buy) | +22,500 | 232,500 | ||
| 2019-02-20 | ERWIN ROBERT L President | Returned to the company · Stock Option (right to buy) | −30,000 | 232,500 | ||
| 2019-02-20 | ERWIN ROBERT L President | Grant or award · Stock Option (right to buy) | +22,500 | 232,500 |
Page 9 of 22 · 423 trades